Liquid Biopsy Market Analyse in New Research Report

1
Liquid Biopsy An Emerging Market for
Radically Improved Cancer Management byInsight
Pharma Reports


Single User
License US 1595 No of Pages NA

Corporate User
License US 9950 Published Feb 2015

• www.rnrmarketresearch.com

WEBSITE
2
Liquid Biopsy An Emerging Market for Radically
Improved Cancer Management

• Cancer diagnostics based on measuring biomarkers
  in tissue samples has already in the past decade
  provided revolutionary advances in diagnosis,
  prognosis, and therapy selection. A major
  drawback of the tissue-based approach centers on
  the need for invasive surgical procedures in
  sample collection, which in a great many
  instances preclude following the progression or
  regression of disease during therapy.
• In recent years, an impressive number of cancer
  biomarker researchers have turned their attention
  to the analysis of markers present in biological
  fluids, which can be collected with minimal
  invasiveness and permit following the disease
  over time. This highly dynamic field has come to
  be called liquid biopsy. In the past few years a
  significant and growing number of startups and
  several major companies have taken up the
  challenge of commercializing and offering liquid
  biopsy products and services to the market
• View Complete Report _at_ http//www.rnrmarketresearc
  h.com/liquid-biopsy-an-emerging-market-for-radical
  ly-improved-cancer-management-market-report.html
  .

3
Liquid Biopsy An Emerging Market for Radically
Improved Cancer Management

• These procedures, for the most part, query blood
  samples for information to be gleaned from
  circulating tumor cells (CTCs), circulating tumor
  DNA (ctDNA) fragments, and extracellular vesicles
  (EVs). CTCs have the longest history as subjects
  for liquid biopsy. Indeed, one decade-old
  commercial product has already garnered FDA
  approval for in vitro diagnostic use. Circulating
  tumor DNA, a more recent entry on the liquid
  biopsy scene, is fast becoming an alternative or
  adjunct to CTC assays. EVs are the newest and
  least developed of the three liquid biopsy sample
  sources, and while highly promising their
  ultimate value has yet to be fully established.
• The report delves deeply into recent progress and
  emerging trends in this highly dynamic area of
  research and commerce. Following an introductory
  chapter that sets the stage for what is to
  follow, Chapter 2 provides a survey of historical
  and evolutionary aspects of liquid biopsy, and
  provides required background and definitions
  helpful in understanding subsequent material.
  Chapter 3 covers basic research activities
  arranged according to the three aforementioned
  analyte classes (CTCs, ctDNA, and EVs).
• Purchase a Copy of this Report _at_
  http//www.rnrmarketresearch.com/contacts/purchase
  ?rname311069 .

4
Liquid Biopsy An Emerging Market for Radically
Improved Cancer Management

• CTCs, the first such entities on the liquid
  biopsy scene, have accounted for much of whats
  been learned to date. However, the relative ease
  of isolating cell-free DNA has quickened research
  activity in this field, and ready access to ctDNA
  has provided important insights that enhance and
  complement those derived from CTCs. EVs, though a
  recent arrival on the liquid biopsy scene, are
  rising rapidly in importance based on their
  perceived ability to add yet another important
  perspective to cancer diagnostics.
• Chapter 4 examines commercial activity in the
  field, including brief profiles of relevant
  companies and status of current and forthcoming
  product offerings. Companies active in CTCs
  include AdnaGen, Angle, ApoCell, Biocept,
  Biofluidica, Clearbridge Biomedics, Cynvenio,
  Cytolumina, CytoTrack, Diagnologix, Epic
  Sciences, Fluxion Biosciences, iCellate, Janssen
  Diagnostics, Qiagen, Rarecells SAS, Silicon
  Biosystems, and SRI International. Biocept and
  Cynvenio exemplify companies that augment their
  CTC assays with ctDNA analysis.
• Companies focused on ctDNA include Agena
  Bioscience, Boreal Genomics, Chronix Biomedical,
  Genomic Health, Guardant Health, Inivata,
  Molecular MD, Myriad Genetics, Natera, Personal
  Genome Diagnostics, Sysmex Inostics, and
  Trovagene. Those active in the EV segment include
  Exosome Diagnostics, Exosome Sciences, and
  HansaBiomed OU.

5
Liquid Biopsy An Emerging Market for Radically
Improved Cancer Management

• Chapter 5, which deals with market dynamics in
  the liquid biopsy space, includes commentary on
  the competitive environment, market size
  estimates and five-year revenue projections,
  tabulation and discussion of deal activity, and
  results from a market survey of more than 100
  individuals active in the field.
• Chapter 6 of the report examines some emerging
  trends that may affect the future development,
  acceptance, and market growth of liquid biopsy.
  Of particular interest are trends in government
  regulation that could possibly limit growth of
  the field, and even in the overall molecular
  diagnostics market. The report also discusses
  issues surrounding the relative merits of the
  three categories of liquid biopsy samples, and
  ways in which they may be competitive or
  complementary. Finally, the chapter examines
  important trends relevant to cancer drug
  resistance and metastasis.
• The final chapter contains transcripts from
  extended interviews with six individuals who are
  highly knowledgeable in the liquid biopsy field.
• Inquire for discount on this report _at_
  http//www.rnrmarketresearch.com/contacts/discount
  ?rname311069 .

6
Liquid Biopsy An Emerging Market for Radically
Improved Cancer Management

• These are
• Nicholas Dracopoli, Ph.D., Vice President
  Oncology Translational Research, Janssen
  Pharmaceuticals
• Paul Dempsey, Ph.D., Chief Scientific Officer,
  Cynvenio Biosystems
• Johan Skog, Ph.D., CSO and Founding Scientist,
  Exosome Diagnostics
• Lidia Sambucetti, PhD, Sr. Director of Cancer
  Biology, and Ted Ira, Director of Sales, SRI
  Biosciences Div.
• Harry Glorikian, Life Sciences Consultant
• Executive SummaryThis report, Liquid Biopsy An
  Emerging Market for RadicallyImproved Cancer
  Management, deals with recent progress and new
  directions in this highly dynamic emerging
  modality for cancer research and in vitro
  diagnostics more

7
Liquid Biopsy An Emerging Market for Radically
Improved Cancer Management

• Background and history
• In the past, biopsied tissue has been evaluated
  for malignancy by highly trained pathologists
  peering through microscopes and applying hard-won
  heuristic knowledge in pattern recognition. Some
  tissue micrographs yield unequivocal results, but
  many do not. Instead, many provide ambiguous data
  that can easily confound interpretation. The
  advent of routine immunohistochemistry improved
  that state of affairs somewhat by adding the
  ability to visualize the presence and
  distribution of certain cellular antigens more
• Basic research
• The availability of sophisticated analytical
  tools for analyzing the contents of cancer cells,
  for detecting genetic variants at extremely low
  allele frequencies, and for isolating
  extracellular vesicles, has in recent years
  triggered a great deal of research using liquid
  biopsy to yield valuable knowledge not readily
  accessible before liquid biopsy became available.
  CTCs, the first such entities on the liquid
  biopsy scene, have accounted for much of whats
  been learned to date more

8
Liquid Biopsy An Emerging Market for Radically
Improved Cancer Management

• Commercial aspects of liquid biopsy
• Janssen Diagnostics CellSearch CTC enumeration
  system dates back more than a decade, and the
  company has enjoyed, essentially, a monopoly in
  the liquid biopsy market, however small its
  been. Recent years have seen rapid growth in the
  number of companies entering the market, many of
  which are backed with substantial venture capital
  funding more
• Market dynamics
• Although liquid biopsy shows great potential to
  extend the capabilities of tissue biopsy and
  possibly even replace it, the modality is still
  in its early days. Considerable inputs of effort
  and investment will be required before the field
  can mature and achieve widespread, routine use in
  oncology clinical practice more
• Trends
• Chapter 6 of the report examines some emerging
  trends that may affect the future development,
  acceptance, and market growth of liquid biopsy.
  Of particular interest are trends in government
  regulation that could limit growth in liquid
  biopsy, and indeed in the overall molecular
  diagnostics market more
• Browse Life Sciences _at_ http//www.rnrmarketresearc
  h.com/reports/life-sciences .

9
RnR Market ResearchRnRMarketResearch.com, an
online repository of market  research reports,
offers in-depth analysis of over 5000 market
segments. RnR  Market Research library has
syndicated reports by leading market research 
publishers across the globe. For more details
contact sales_at_rnrmarketresearch.com /
18883915441FOLLOW US
Website
www.rnrmarketresearch.com